Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
Dow
McKinsey
Moodys

Last Updated: May 19, 2022

CLINICAL TRIALS PROFILE FOR BRIVIACT


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Briviact

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00160667 ↗ A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia) Completed UCB Pharma Phase 2 2004-10-11 Study will assess efficacy, safety and tolerability of brivaracetam in post-herpetic neuralgia (PHN). Duration of 7 weeks divided into 3 periods with no up-titration, nor down-titration.
NCT00175825 ↗ A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures. Completed UCB Pharma Phase 2 2005-11-07 This trial will evaluate the efficacy and safety of brivaracetam (at doses of 5, 20 and 50 mg/day in twice a day administration) as add-on therapy in subjects with focal epilepsy.
NCT03021018 ↗ A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting Completed UCB Biopharma S.P.R.L. Phase 2 2017-02-06 The purpose of this study is to assess the efficacy of intravenous brivaracetam (BRV) compared to intravenous lorazepam (LZP) in subjects with epilepsy undergoing Epilepsy Monitoring Unit (EMU) evaluation who experience seizures that require prompt treatment.
NCT03083665 ↗ A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy Recruiting UCB Biopharma S.P.R.L. Phase 3 2017-08-22 The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.
NCT03083665 ↗ A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy Recruiting UCB Biopharma SRL Phase 3 2017-08-22 The purpose of the study is to evaluate the efficacy of brivaracetam (BRV) compared to placebo (PBO) as adjunctive treatment in subjects (>=16 to 80 years of age) with partial seizures with or without secondary generalization despite current treatment with 1 or 2 concomitant antiepileptic drugs (AEDs) and to assess the safety and tolerability of BRV in subjects >= 16 years to 80 years of age.
NCT03250377 ↗ A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization Enrolling by invitation UCB Biopharma S.P.R.L. Phase 3 2017-08-05 The purpose of the study is to evaluate the long-term safety and tolerability of Brivaracetam (BRV) in focal epilepsy subjects with partial seizures and to evaluate the maintenance of efficacy of BRV over time.
NCT03325439 ↗ A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures Recruiting UCB Biopharma S.P.R.L. Phase 2/Phase 3 2019-05-07 The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the optimal BRV dose (Exploratory Cohort) for the treatment of subjects enrolled into the Confirmatory Cohorts of this study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Briviact

Condition Name

Condition Name for Briviact
Intervention Trials
Epilepsy 7
Partial Seizures With or Without Secondary Generalization 3
Electroencephalographic Neonatal Seizures 1
Healthy Participants 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Briviact
Intervention Trials
Epilepsy 7
Seizures 6
Neoplasm Metastasis 3
Neuralgia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Briviact

Trials by Country

Trials by Country for Briviact
Location Trials
United States 46
Germany 4
Japan 4
France 3
Mexico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Briviact
Location Trials
North Carolina 4
New York 4
Florida 3
Arizona 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Briviact

Clinical Trial Phase

Clinical Trial Phase for Briviact
Clinical Trial Phase Trials
Phase 3 4
Phase 2/Phase 3 1
Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Briviact
Clinical Trial Phase Trials
Completed 6
Recruiting 4
Enrolling by invitation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Briviact

Sponsor Name

Sponsor Name for Briviact
Sponsor Trials
UCB Biopharma S.P.R.L. 6
UCB Biopharma SRL 4
UCB Pharma 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Briviact
Sponsor Trials
Industry 12
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Harvard Business School
Johnson and Johnson
AstraZeneca
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.